A number of other research firms also recently weighed in on ADMS. Mizuho reaffirmed a buy rating and set a $48.00 price target on shares of Adamas Pharmaceuticals in a research note on Tuesday, January 23rd. BidaskClub raised Adamas Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, January 25th. ValuEngine raised Adamas Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, February 2nd. Zacks Investment Research raised Adamas Pharmaceuticals from a hold rating to a buy rating and set a $40.00 price target on the stock in a research note on Wednesday, January 3rd. Finally, Cowen set a $55.00 price target on Adamas Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, December 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $45.14.
Adamas Pharmaceuticals (NASDAQ:ADMS) opened at $25.95 on Friday. The stock has a market capitalization of $667.34, a PE ratio of -5.15 and a beta of 1.17. The company has a debt-to-equity ratio of 1.55, a current ratio of 10.79 and a quick ratio of 10.69. Adamas Pharmaceuticals has a 52 week low of $13.50 and a 52 week high of $44.00.
A number of hedge funds have recently bought and sold shares of ADMS. JPMorgan Chase & Co. increased its holdings in Adamas Pharmaceuticals by 13,028.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 136,273 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after purchasing an additional 135,235 shares in the last quarter. Hikari Power Ltd bought a new stake in Adamas Pharmaceuticals during the 3rd quarter worth approximately $635,000. EAM Investors LLC bought a new stake in Adamas Pharmaceuticals during the 3rd quarter worth approximately $1,795,000. Vanguard Group Inc. increased its holdings in Adamas Pharmaceuticals by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 745,237 shares of the specialty pharmaceutical company’s stock worth $13,034,000 after purchasing an additional 28,818 shares in the last quarter. Finally, Deltec Asset Management LLC bought a new stake in Adamas Pharmaceuticals during the 4th quarter worth approximately $3,399,000. 66.90% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3224425/adamas-pharmaceuticals-adms-buy-rating-reiterated-at-noble-financial.html.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.